drugset
drugset / Trial / NCT02603926

Treatment of Fragile-X Associated Tremor/Ataxia Syndrome (FXTAS) With Allopregnanolone

NCT02603926 ↗

Phase 2 Completed 6 enrolled Randi J. Hagerman, MD
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study is to examine the safety and efficacy of Allopregnanolone as a possible treatment for symptoms of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS).

Timeline

Start
2015-10
Primary completion
2016-12
Completion
2017-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Allopregnanolone Small molecule 2 mg Intravenous
Subject Allopregnanolone Small molecule 4 mg Intravenous
Subject Allopregnanolone Small molecule 6 mg Intravenous

Indications

fragile X-associated tremor/ataxia syndrome